Selective C-KIT kinase inhibitor
US10793543B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 28, 2017 |
| Grant date | Oct 6, 2020 |
| Priority date | — |
| Expiry date | Mar 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/14
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a compound represented by formula (I), or a pharmaceutically acceptable salt, a solvate, an ester, an acid, a metabolite or a prodrug thereof. The compound itself in the present invention or in combination with at least one therapeutic agent can be used for preventing or treating diseases, disorders or symptoms caused by the adjustment of the activity of tyrosine kinase C-KIT, or affected by the activity of the tyrosine kinase C-KIT or involving in the activity of the tyrosine kinase C-KIT, especially cancers or other cell proliferation diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.